Cargando…

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease

When differential diagnosis of dementia includes both Alzheimer's disease (AD) and the behavioural variant of frontotemporal dementia (bvFTD), distribution of cerebral glucose metabolism as measured using [(18)F]‑2‑fluoro‑2‑deoxy‑d‑glucose positron emission tomography ([(18)F]FDG-PET) may be he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheltens, Nienke M.E., van der Weijden, Kars, Adriaanse, Sofie M., van Assema, Danielle, Oomen, Priscilla P., Krudop, Welmoed A., Lammertsma, Adriaan A., Barkhof, Frederik, Koene, Teddy, Teunissen, Charlotte E., Scheltens, Philip, van der Flier, Wiesje M., Pijnenburg, Yolande A.L., Yaqub, Maqsood, Ossenkoppele, Rik, van Berckel, Bart N.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030576/ https://www.ncbi.nlm.nih.gov/pubmed/29984170 http://dx.doi.org/10.1016/j.nicl.2018.05.024

Ejemplares similares

Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease
por: Adriaanse, Sofie M., et al.
Publicado: (2014)

The natural history of primary progressive aphasia: beyond aphasia
por: Ulugut, Hulya, et al.
Publicado: (2021)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

A clinical-radiological framework of the right temporal variant of frontotemporal dementia
por: Ulugut Erkoyun, Hulya, et al.
Publicado: (2020)

Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin?
por: Verfaillie, Sander C. J., et al.
Publicado: (2015)

Differential trajectories of hypometabolism across cognitively-defined Alzheimer’s disease subgroups
por: Groot, Colin, et al.
Publicado: (2021)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Schizophrenia as a mimic of behavioral variant frontotemporal dementia
por: Kerssens, Cora J., et al.
Publicado: (2016)

Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
por: Eikelboom, Willem S., et al.
Publicado: (2021)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory
por: de Haan, Willem, et al.
Publicado: (2009)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Psychosis in behavioral variant frontotemporal dementia
por: Gossink, Flora T, et al.
Publicado: (2017)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity
por: Louwersheimer, Eva, et al.
Publicado: (2017)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Visual assessment of posterior atrophy development of a MRI rating scale
por: Koedam, Esther L. G. E., et al.
Publicado: (2011)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
por: Verfaillie, Sander C. J., et al.
Publicado: (2019)

Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
por: Heeman, Fiona, et al.
Publicado: (2022)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia
por: van Straaten, Elisabeth CW, et al.
Publicado: (2012)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

A novel CCM2 variant in a family with non‐progressive cognitive complaints and cerebral microbleeds
por: Cohn‐Hokke, Petra E., et al.
Publicado: (2016)

Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship
por: van Loenhoud, Anna Catharina, et al.
Publicado: (2019)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0bo8kb78njpp8dbbgcb8sotekm